

HEALTHY HEART

VOLUME-16 | ISSUE-188 | JULY 05, 2025

Price : ₹ 5/-





Honorary Editor :



Dr. Hemang Baxi

Interventional Cardiologist



Isolated Systolic Hypertension

Case History

A 75-year-old man who is a care taker for his disabled wife.

He is quite active and copes well with household chores. He has high cholesterol and takes a statin as well as aspirin. Blood pressure (BP) has been high for some time, and at the visit is 168/82. The time has come to start treatment, and you wish to discuss this with him. Renal function and creatinine are both normal. Urine is negative on stick testing but he has microalbuminuria on laboratory testing.

- Is ISH common, and is it important?
- Why does Systolic BP (SBP) selectively increase in the elderly?
- What is the optimal approach to management?

The relative increase in SBP, compared with DBP, relates to decreased vascular compliance with ageing. The latter arises from atherosclerosis, collagen cross-linking and glycosylation, vascular calcification and elastin fragmentation. The aorta and larger

vessels lose the ability to expand to accommodate the pulse wave during systole and there is decreased recoil during diastole. Decreased baroreceptor responses and increased salt sensitivity contribute to hypertension in the elderly. Although plasma catecholamines are relatively increased, sensitivity of adrenoreceptors is decreased. Increased

sympathetic drive is, therefore, a less important mechanism and because of this as well as often decreased myocardial function, increased cardiac output is less important than in younger subjects. Activation of the




Figure-1 : Change in blood pressure with age.

renal artery stenosis is also relatively less important in ISH, explaining why

Cardiologists

Dr Tejas V. Patel	(M) +91-89403 05130
Dr Hiren Kevadiya	(M) +91-98254 65205
Dr Gunvant Patel	(M) +91-98240 61266
Dr Keyur Parikh	(M) +91-98250 26999
Dr Milan Chag	(M) +91-98240 22107
Dr Urmil Shah	(M) +91-98250 66939
Dr Hemang Baxi	(M) +91-98250 30111
Dr Anish Chandarana	(M) +91-98250 96922
Dr Ajay Naik	(M) +91-98250 82666
Dr Satya Gupta	(M) +91-99250 45780
Dr Vipul Kapoor	(M) +91-98240 99848
Dr Vineet Sankhla	(M) +91-99250 15056

Cardiothoracic & Vascular Surgeons

Dr Dhiren Shah	(M) +91-98255 75933
Dr Dhaval Naik	(M) +91-90991 11133
Dr Amit Chandan	(M) +91-96990 84097
Dr Nikunj Vyas	(M) +91-73531 65955
Dr Dhyanil Trivedi	(M) +91-99989 67576

Congenital & Structural Heart Disease Specialist

Dr Kashyap Sheth	(M) +91-99246 12288
Dr Milan Chag	(M) +91-98240 22107

Paediatric & Structural Heart Surgeon

Dr Shaunak Shah	(M) +91-98250 44502
-----------------	---------------------

Cardiovascular, Thoracic & Thoracoscopic Surgeon

Dr Pranav Modi	(M) +91-99240 84700
----------------	---------------------

Cardiac Anaesthetists

Dr Niren Bhavsar	(M) +91-9879571917
Dr Hiren Dholakia	(M) +91-9586375818
Dr Chintan Sheth	(M) +91-9173204454

Cardiac Electrophysiologist

Dr Ajay Naik	(M) +91-98250 82666
Dr Hiren Kevadiya	(M) +91-98254 65205



angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are often not the most effective drugs. The addition of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers to treatment is logical where ISH is placing the patient in danger of end-organ damage. There is particularly strong evidence that these agents may bring about regression of left ventricular hypertrophy and retard




Figure-2 : Presentation of untreated hypertension. IDH, isolated diastolic hypertension; ISH, isolated systolic hypertension; S-D, systolic-diastolic (essential) hypertension. Adapted from Chobanian.

the development of nephropathy. Salt sensitivity is increased in older subjects, and this contributes to increased arterial stiffness. Thus, lower salt intake and diuretic therapy are central in management. ISH and essential hypertension are compared in Table 1.

Even a modest decrease in SBP of <5 mmHg reduces cardiac mortality by 7% and stroke mortality by 10%. A target BP of 140/90 seems reasonable for the elderly, but is often not achievable, let alone the tighter target of 130/80, which is recommended for those at higher risk (e.g. those with diabetes and chronic kidney disease). Effective treatment of ISH decreases the risk of

Table-1 : ISH and essential hypertension

	Essential	ISH
Increase cardiac output	+	—
Arterial compliance	+	—
Peripheral resistance	++	+
Left ventricular mass	+	++
Baroreceptor sensitivity	— —	—
Plasma catecholamines	+	++
Plasma renin	—	—
Salt sensitivity	+	++
Adapted from Pannarale.		

CV events by 23%. The landmark trials in this area (see Duprez for a review) were:

- SHEP (1991) followed 4736 patients with ISH for 4.5 years. In treated patients, the rate of non-fatal stroke was decreased by 36%, cardiac disease by 25%, and heart failure by 53%. A more recent (2005) extension of this study following patients for up to 14.3 years showed continuing benefit in terms of event rate reduction. Benefit extended to those with pre-existing diabetes, while those who
- developed diabetes during the follow-up period but had their BP treated had no different risk to patients without diabetes. This study was based on the use of chlorthalidone with other agents added as needed.
- Syst-Eur (1997) and Syst-China (1998) followed 4695 and 2394 patients respectively for 2-3 years, with initial therapy based on Calcium Channel Blockers (CCB).

These studies showed a reduction in stroke of about 40% and of total CV outcomes of 31-39% for treated patients.

More recent studies have included: LIFE (2002) in which losartan decreased CV out-comes compared with an atenolol-based regimen in 1326 patients with ISH and left ventricular hypertrophy followed for 4.7 years; the Systolic Hypertension in the Elderly Long-term Lacidipine study (SHELL, 2003) in which 1882 patients with ISH were followed for 32 months, showed a 9.3% reduction in event rate with the CCB; the Intervention as a Goal in Hypertension Treatment study (INSIGHT, 2004) which included 1498 patients with ISH followed for 3 years, and showed a 6% decrease in the CV event rate. These, and a number of other short-term studies have, in recent years, highlighted ISH as a clinical problem in the elderly. They have also shown that decreasing BP leads to lower CV risk. Although the various classes of agent are similar in



BP-decreasing potency, rennin-angiotensin system blocking drugs and CCBs have the most trial evidence. The former may be slightly superior in preventing stroke and are slightly better tolerated because of the relatively high incidence of peripheral oedema seen with CCBs.

Treatment of ISH

As with all patients with hypertension, the elderly with ISH should have an overall assessment of CV risk, secondary causes of hypertension should be considered (particularly renovascular) and they should be screened for end-organ damage (eyes, heart and kidneys). Consider also conditions that increase cardiac output and may selectively increase SBP. These include anaemia,

thyrotoxicosis, Paget's disease and aortic regurgitation. Lifestyle modifications should be instituted where possible – maintain or decrease body weight, regular exercise, balanced diet, lower salt intake and avoid excess alcohol. It is assumed that the major advantage of drug treatment is through lowering BP, and none of the major classes has a specific action in ISH. In the elderly, it is important to start with low doses of drugs where possible, and to titrate gradually with careful monitoring of BP response, renal function and electrolytes. Over-vigorous reduction in DBP should be avoided as this may decrease myocardial perfusion.

The first choice of treatment for ISH is low-dose thiazide. The greatest evidence is with hydrochlorothiazide and chlorthalidone. Bendrofluazide is also widely used. The latter is more potent on a milligram for milligram basis and also has a longer half-life (48-72h vs 16-24 h). The disadvantages of thiazides are hypokalemia, increased

uric acid, dyslipidaemia, hyperglycaemia, and erectile dysfunction in men. All of these are common in the elderly but less likely to occur with low doses – 12.5 mg of hydrochlorothiazide is a suitable starting dose. Long-acting CCBs should also be considered early in the treatment. These are of proven efficacy and have beneficial effects on vascular remodelling. B-blockers are no

longer considered first-line for the elderly patient with ISH, but should certainly be used in those with angina or previous myocardial infarction, and considered in those with heart failure (Figure 3).

Recent Developments

1. High SBP is very variable in older subjects with reduced vascular




Figure-3 : Management of ISH. CCF, congestive cardiac failure; CKD, chronic kidney disease.



compliance. There is an argument for confirming ISH on at least three occasions before the diagnostic label is assigned. A recent large Portuguese study confirmed that ISH was common, particularly after the age of 70. It was not, however, particularly associated with premature mortality, and CV complications often developed very late in life.

2. In a follow-up of participants in the SHEP trial at 14.3 years, a chlor-thalidone-based antihypertensive regimen decreased CV mortality – RR 0.86 (95% CI:0.76 to 0.98). Patients who had sustained stroke experienced a particularly poor mortality experience. We should not be over-pessimistic about the dangers of ISH, or over-optimistic about the benefits of treatment. For population-based risk reduction, many patients would have to be treated for many years to appreciably impact on mortality.

3. Over-aggressive treatment of systolic hypertension may lead to an unwanted decrease in DBP. In the elderly, DBP <60 mmHg has been associated with poor

prognosis independent of large artery stiffness and left ventricular function. Elderly people taking antihypertensives should be carefully monitored. DBP decreases with age and may warrant altering treatment for ISH.

4. Long-acting CCBs are a very useful adjunct to thiazides as first-line treatment. A recent trial compared amlodipine with a newer CCB manidipine. Chlorthalidone was added where needed. Both CCBs effectively decreased BP. Manidipine had

the advantage of a lower incidence of peripheral oedema.

5. The importance of exercise as an intervention for the elderly is often forgotten. Apart from general well-being, exercise has tangible benefits including reducing SBP. Given the now proven benefits of exercise in elderly patients with chronic disease, including diabetes and pulmonary disease, we need to examine how to actively engage elderly people in exercise programmes.

Conclusions

The vast majority of us will develop hypertension as we age, and ISH is by far the commonest form in older people. Subtly, the pathogenesis is different to that of essential hypertension, which is a disease of younger people. Decreased vascular compliance is the hallmark. The underlying cause of hypertension shifts from more humoral mechanisms in

younger subjects to more mechanical causes in the elderly. This explains why some drugs are less effective in ISH. The condition is important, being strongly linked with adverse CV outcomes, particularly stroke. Treatment with two or more drugs is often needed. Over-vigorous

treatment may control ISH but at the expense of undue lowering of DBP, which may reduce coronary perfusion. Low-dose thiazides and long-acting CCBs are the cornerstone of treatment. These should be initiated cautiously and titrated gradually, especially in very aged or frail patients.



ONE LIFE
ONE DESTINATION
CARDIAC SCIENCE
MARENGO CIMS HOSPITAL

Leaders in
Transplants Across India

60TH HEART

TRANSPLANT JUNE 20, 2025

Heartfelt gratitude to the donors for passing the

Baton of Life!



HEALTHY HEART


VOLUME-16 | ISSUE-188 | JULY 05, 2025



**ONE LIFE
ONE DESTINATION**
CARDIAC SCIENCE
MARENGO CIMS HOSPITAL



**BEST HOSPITAL
IN AHMEDABAD FOR
4 CONSECUTIVE YEARS**
AMONGST TOP 25 IN INDIA
Thank you for trusting us with your health



INSTITUTE OF CARDIAC SCIENCES

THE MOST TRUSTED CARDIAC TEAM

Cardiac MRI

4-D ECHO

CT Coronary Angiography

OCT | IVUS | FFR

Centre of Excellence for EP,
PACEMAKERS, CRT/D, ICD, 3-D CARTO

• Interventional Cardiology •

- Coronary Angiography • Coronary Angioplasty • Peripheral & Carotid Angioplasty
- Device Therapy for Heart Failure • Renal Denervation Therapy (RDN)
- Percutaneous Intervention for Structural heart diseases TAVI/TAVR
- Electrophysiology Studies • Left Ventricular Assist Device (LVAD) Implantation
- Balloon Valvuloplasty

• Cardiac Surgery •

- Minimally Invasive Heart Surgery (MICS) • Bypass Surgery (CABG) • Aortic Surgery
- Heart Valve Surgery • Heart Failure Surgery • Robotic Bypass Surgery
- Paediatric Cardiac Surgery

• Disease-Specific Clinics •

- Heart Transplant Clinic
- STEMI initiative
- Structural and Valvular Clinic & STROKE Centre
- Heart Failure Clinic
- Arrhythmia Clinic
- Cardio-Oncology Clinic

Marengo CIMS Hospital

Off. Science City Road, Sola, Ahmedabad - 380060.



JCI (USA)

1800 309 9999



NO TWO HEARTS ARE THE SAME

7 DIFFERENT WAYS perfected for Bypass Surgery



- On Pump (Open Heart) Surgery
- Off Pump (Beating Heart) Surgery
- Bilateral Internal Mammary Artery (BIMA) Total Arterial Bypass Surgery
- Minimally Invasive Cardiac Surgery (MICS)
- Robotics Heart Bypass Surgery
- Hybrid Bypass Surgery
- Bypass Surgery in Heart Failure

For Appointment: +91 82380 95712 | +91 82380 95715

Marengo CIMS Hospital

Off. Science City Road, Sola, Ahmedabad - 380060



JCI (USA)

☎ 1800 309 9999



HEALTHY HEART

VOLUME-16 | ISSUE-188 | JULY 05, 2025

Healthy Heart Registered under **RNI No. GUJENG/2008/28043**

Published on 5th of every month

Permitted to post at PSO, Ahmedabad-380002 on the 12th to 17th of every month under
Postal Registration No. **GAMC-1725/2024-26** issued by SSP Ahmedabad valid upto 31st December, 2026
Licence to Post Without Prepayment No. **PMG/NG/055/2024-26** valid upto 31st December, 2026

If undelivered Please Return to :

CIMS Hospital,
Nr. Shukan Mall, Off Science City Road,
Sola, Ahmedabad-380060.
Call : 1800 309 9999

Subscribe "Healthy Heart" : Get your "Healthy Heart", the information of the latest medical updates only ₹ 60/- for one year.
To subscribe pay ₹ 60/- in cash or cheque/DD at CIMS Hospital Pvt. Ltd. Nr. Shukan Mall, Off Science City Road, Sola,
Ahmedabad-380060. Phone : +91-79-4805 2823. Cheque/DD should be in the name of : **"CIMS Hospital Pvt. Ltd."**
Please provide your **complete postal address with pincode, phone, mobile and email id** along with your subscription

From Dialysis to Dreams

Celebrating a Landmark in Kidney Care.

158
KIDNEY TRANSPLANTS

In a Span of **2** Years

Leading the nation in transplant care!



Printed, Published and Edited by Dr. Keyur Parikh on behalf of the CIMS Hospital

Shakti Offset, A-62, Pushraj Industrial Estate, Nutan Mill Road, Behind - Adani CNG Station, Saraspur, Ahmedabad - 380 018
Published from CIMS Hospital, Nr. Shukan Mall, Off Science City Road, Sola, Ahmedabad-380060.